Although BTK inhibitors have shown promising efficacy and have become the standard of care for treating chronic lymphocytic leukemia, mantle cell lymphoma, and marginal zone B-cell lymphoma as single agents5, the efficacy of BTK inhibitor monotherapy for aggressive large B-cell lymphoma has not been satisfactory. This evidence concerns the gene BTK and mantle cell lymphoma.